<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:type xml:lang="eng">Text</dc:type>
  <dc:type xml:lang="eng">journal article</dc:type>
  <dc:type xml:lang="ita">Testo</dc:type>
  <dc:type xml:lang="ita">Articolo di rivista</dc:type>
  <dc:subject xml:lang="eng">P-Glycoprotein</dc:subject>
  <dc:subject xml:lang="eng">Blood-Brain Barrier</dc:subject>
  <dc:subject xml:lang="eng">PET</dc:subject>
  <dc:subject xml:lang="eng">[11C]metoclopramide</dc:subject>
  <dc:subject xml:lang="eng">Heterozygous Abcb1a/b Knockout Mice</dc:subject>
  <dc:creator>Severin Mairinger</dc:creator>
  <dc:creator>S. Leterrier</dc:creator>
  <dc:creator>Thomas Filip</dc:creator>
  <dc:creator>Mathilde Loebsch</dc:creator>
  <dc:creator>Jens Pahnke</dc:creator>
  <dc:creator>Irene Hernández-Lozano</dc:creator>
  <dc:creator>J. Stanek</dc:creator>
  <dc:creator>Nicolas Tournier</dc:creator>
  <dc:creator>Markus Zeitlinger</dc:creator>
  <dc:creator>Marcus Hacker</dc:creator>
  <dc:creator>Oliver Langer</dc:creator>
  <dc:creator>Thomas Wanek</dc:creator>
  <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
  <dc:date>2024</dc:date>
  <dc:source xml:lang="eng">Journal Of Cerebral Blood Flow And Metabolism</dc:source>
  <dc:publisher>Sage</dc:publisher>
  <dc:title xml:lang="eng">[11C]metoclopramide is a sensitive radiotracer to measure moderate decreases in P-glycoprotein function at the blood-brain barrier</dc:title>
  <dc:rights xml:lang="eng">Copyright © 2024</dc:rights>
  <dc:rights xml:lang="eng">open access</dc:rights>
  <dc:description xml:lang="eng">The efflux transporter P-glycoprotein (P-gp) at the blood-brain barrier limits the cerebral uptake of various xenobiotics. To assess the sensitivity of [11C]metoclopramide to measure decreased cerebral P-gp function, we performed [11C]metoclopramide PET scans without (baseline) and with partial P-gp inhibition by tariquidar in wild-type, heterozygous Abcb1a/b(+/−) and homozygous Abcb1a/b(−/−) mice as models with controlled levels of cerebral P-gp expression. Brains were collected to quantify P-gp expression with immunohistochemistry. Brain uptake of [11C]metoclopramide was expressed as the area under the brain time-activity curve (AUCbrain) and compared with data previously obtained with (R)-[11C]verapamil and [11C]N-desmethyl-loperamide. Abcb1a/b(+/−) mice had intermediate P-gp expression compared to wild-type and Abcb1a/b(−/−) mice. In baseline scans, all three radiotracers were able to discriminate Abcb1a/b(−/−) from wild-type mice (2.5- to 4.6-fold increased AUCbrain, p ≤ 0.0001). However, only [11C]metoclopramide could discriminate Abcb1a/b(+/−) from wild-type mice (1.46-fold increased AUCbrain, p ≤ 0.001). After partial P-gp inhibition, differences in [11C]metoclopramide AUCbrain between Abcb1a/b(+/−) and wild-type mice (1.39-fold, p ≤ 0.001) remained comparable to baseline. There was a negative correlation between baseline [11C]metoclopramide AUCbrain and ex-vivo-measured P-gp immunofluorescence (r = −0.9875, p ≤ 0.0001). Our data suggest that [11C]metoclopramide is a sensitive radiotracer to measure moderate, but (patho-)physiologically relevant decreases in cerebral P-gp function without the need to co-administer a P-gp inhibitor.</dc:description>
  <dc:identifier>doi:10.1177/0271678X231202336</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:type xml:lang="deu">Text</dc:type>
  <dc:type xml:lang="deu">Wissenschaftlicher Artikel</dc:type>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://phaidra.vetmeduni.ac.at/o:4452</dc:identifier>
</oai_dc:dc>